The autologous red cell agglutination assay reagent consists of an antibody or antibody fragment of a human erythrocyte-specific monoclonal antibody (mAb) conjugated to an antigen of interest. This bi-functional reagent causes the agglutination of the patient's erythrocytes in the presence of the antigen-specific antibodies in the patient's serum. 
Introduction
The autologous red cell agglutination technology was developed and commercialised by AGEN Biomedical Ltd. for the rapid detection of circulating antibodies of clinical interest.
The technology is based on a monoclonal antibody (mAb) which binds to but does not agglutinate erythrocytes. If a diagnostic peptide is conjugated to the mAb, peptide-specific antibodies in patient sera crosslink erythrocytes through the mAb and mediate easily observable agglutination within two minutes (Kemp et al., 1988; Rylatt et al., 1990; Hillyard et al., 1991) . The technology has been applied in a commercial assay to detect antibodies in Human Immunodeficiency virus (HIV)-infected patients, with sensitivities and specificities of greater than 99% Wilson et al., 1991) .
The autologous red cell agglutination technology represents a simple and robust rapid diagnostic assay platform based on a single reagent. Because the read-out system is the patient's own erythrocytes, there is no need for secondary reagents such as fluorophore-or gold-labelled antibodies, reagent-coated latex beads or fixed heterologous erythrocytes. The assay is performed on a simple plastic tray, which avoids the need for more complicated devices such as those required for immunochromatographic technologies. However, broader exploitation of this technology has been hindered by the conjugation protocols required to produce the diagnostic reagents Wilson et al., 1991) . The mAb must be reduced to an Fab fragment and chemically conjugated to the synthetic peptide in a process requiring several purification steps. A separate chemical protocol must be developed for each diagnostic analyte. The presence of heterophile (anti-mouse immunoglobulin (Ig)) antibodies also complicates the interpretation of the assay results and has led to the inclusion of mouse immunoglobulin in the reaction mix.
To overcome these barriers to greater use of the technology, several groups have explored the use of recombinant reagents. The feasibility of this approach was established initially in a bacterial expression system that used a single chain Fv fragment (scFv) derived from the original anti-erythrocyte mAb. The DNA encoding the scFv was linked to that encoding the HIV gp41 peptide to produce a functional reagent (Lilley et al., 1994; Coia et al., 1996) .
Although the performance of the recombinant molecule was equivalent to that of the chemically conjugated reagent, the yield of recombinant was considered unacceptable for commercial purposes.
Anti-erythrocyte Fab fusion proteins have also been described. In one approach, an Fab with HIV-1 and HIV-2 terminal fusion peptides was expressed using a system which induced secretion of the recombinant proteins into the bacterial periplasmic space, where proper chain folding and disulphide bond formation could take place (Dolezal et al., 1995) . In another approach, an anti-erythrocyte Fab-HIV peptide fusion protein was produced through cytosolic expression as inclusion bodies in Escherischia coli (Gupta et al., 2001; Gupta and Chaudhary, 2002 . Although functional reagents were produced with both methods, the recovery of the reagent involved extensive extraction and purification procedures, as is common with other bacterial systems (for example, Choi et al., 2004) . Similarly, in the approach used by Gupta et al., (2001) the recombinant molecules were extracted from the inclusion bodies by solubilisation and denaturation, followed by renaturation to assemble the Fab. The published protocol resulted in a pure reagent, but it involves several purification steps that appeared to span many days.
In the decade since the original publications describing the recombinant scFv-HIV reagent, there have been significant advances in protein expression systems. scFvs have been produced in bacterial, mammalian, yeast and insect cell systems with varying success in terms of yield and function (Ridder et al., 1995; Kretzschmar et al., 1996; Sanchez et al., 1999; Fernandez et al., 2000; Freyre et al., 2000; Dai et al., 2003) . Increasing numbers of recombinant therapeutics are being manufactured using mammalian expression systems (Wurm, 2004) . These systems ensure that there is authentic post-translational modification of the recombinant versions of proteins expressed naturally in mammalian cells, such as antibodies, hormones, cytokines and viral proteins. The secretion of the protein into the cell culture medium, especially synthetic serum-free medium, facilitates simple protein purification (Dorai et al., 1994) . Although the reported protein yields vary, fed-batch fermentation can yield 0.5 to 2 g/L protein (Bebbington et al. 1992; Zhou et al. 1997 ).
The studies reported in this article were undertaken to assess the feasibility of mammalian expression systems for the production of recombinant autologous agglutination reagents for use in antibody-detection assays. In particular, the aim was to develop a system based on generic vectors into which antigenic peptides could be incorporated rapidly and one in which the culture supernatant could be used for agglutination reactions without further processing.
Recombinant expression of these agglutination reagents would enable rapid, on-demand production for minimal cost. This is particularly important for developing countries where outbreaks of new pathogens are frequent and there is a requirement for inexpensive, 'point-ofcare' assays. Such a system will be very useful in response to the emergence of new pathogens.
Materials and Methods

Antibodies
The anti-erythrocyte and anti-D-dimer mAb and fragments were supplied as purified proteins by AGEN Biomedical Ltd (Brisbane, Australia). The anti-erythrocyte (specifically, antihuman glycophorin A, Rylatt et al., 1990) Hobson-Peters et al., 2008) . A pool of sera from WNV-naïve horses was used as an additional negative control.
Polymerase chain reaction (PCR) protocol
PCR was performed in a final volume of 25 μL. The reaction mix comprised 10 mM Tris-Cl pH 8.3, 50 mM KCl, 2.5 mM MgCl 2 , 200 -300 µM each dNTP (Sigma-Aldrich, Saint Louis, recombinant version of the full-length mAb 1C3 was based on plasmids which encode the Ddimer-specifc mAb 3B6. These plasmids, pSVhygHuC K and pSVgptHuIgG 1 , separately encode the mAb 3B6 light and heavy variable region genes linked to the human kappa light chain and IgG 1 heavy chain genes, respectively (Macfarlane et al., 2006) . The cloning strategy, as outlined in Fig. 1 , was to substitute the mAb 3B6 variable regions in the two plasmids with those of mAb 1C3. In brief, the original pSV vectors were digested with
HinDIII and BamHI to release the immunoglobulin signal peptide and 3B6 variable regions.
These were replaced with the 1C3 variable regions which had been generated by using overlap PCR to ligate three PCR products: DNA encoding the immunoglobulin signal peptide with HinDIII site amplified from the original pSV vectors, either the mAb 1C3 V L or V H region genes amplified from the mAb 1C3 scFv bacterial plasmid pGC038C L (Coia et al., 1996) and the 3' region of the parental pSV vector containing splice sequences and the BamHI site. The plasmids were named pSV1C3V L and pSV1C3V H .
The construction of a plasmid to express chimeric mAb 1C3 with the WNV epitope WN19
attached to the C-terminus of the heavy chain was done in two steps (Fig. 2 ). An intermediate construct (pSV1C3VHI) was produced, in which the stop codon at the end of heavy chain was removed and two unique, non-complementary restriction enzyme sites, XhoI and EagI, were inserted. The sequence encoding WN19 was amplified from pCBWN (Davis et al., 2001 ) and inserted into pSV1C3VHI using these two sites. An additional restriction enzyme site (BspE1) was incorporated at the 3' end of the peptide WN19 sequence to facilitate future insertions via the XhoI and BspEI sites. This design also enables replacement of peptide WN19 through XhoI/EagI or BspEI/EagI digestion. The primers used in the cloning reactions are indicated in Figs. 1 and 2 and listed in Table 1 . To confirm that the expected constructs had been prepared, the plasmids were sequenced by the Australian Genome Research Facility (AGRF, Brisbane) by ABI Prism BigDye Terminator version 3.1. At least one forward and one reverse reaction were submitted for each plasmid.
Glycophorin ELISA
The wells of an ELISA plate (Greiner Bio-one GnbH, Neuburg, Germany) were coated with glycophorin A (Sigma-Aldrich, Saint Louis, MO, USA) in coating buffer (50 mM NaHCO 3 , 50 mM Na 2 CO 3 pH9.6) for either 1 h at room temperature with gentle agitation, or overnight at 4 °C. The wells were washed three times with phosphate buffered saline (PBS) containing 0.05% Tween 20 (PBS/T) and blocked with 5% skim milk in PBS (100 L) for 1 h. The ELISA was optimised using a checkerboard titration of human glycophorin A (200 -6.25 ng/well) and mAb 1C3 (anti-glycophorin A) or 3A1/48 (negative control mAb, Bundesen et al., 1985) Fab (800 -0.0018 ng/well), using the conditions described below. The optimal concentration of glycophorin A was 50 ng/well and was used for all subsequent assays.
The recombinant proteins were added as cell lysates (COS cells) or culture supernatants (NS0 cells, undiluted or diluted 1:2 or 1:6). The cell lysates were prepared by harvesting with a cell scraper into PBS. The scFv proteins were detected with goat anti-mouse Ig, followed by HRP-conjugated rabbit anti-goat Ig, as described above. The recombinant mAb 1C3 was detected using a 1:1000 dilution of rabbit anti-human IgG (Dako, Glostrup, Denmark), followed by HRP-conjugated goat anti-rabbit Ig (Dako, Glostrup, Denmark, 1:1000 
N-glycosidase F (PNGase F) digestion
The recombinant proteins, as COS cell lysates, were digested with PNGase F (NEB, Ipswich, MA, USA) according to the manufacturer's instructions, as in Hobson-Peters et al. (2008) .
Western blot
Antigens were mixed with 1 x NuPage LDS sample buffer (Invitrogen, Carlsbad, CA, USA). 
Ammonium Sulphate precipitation of recombinant scFv fusion proteins
Ammonium sulphate precipitation of the recombinant scFv proteins from cell culture supernatant was performed as described by Wang et al. (2001) . Briefly, the cell culture supernatant of stable NS0 cell lines growing in CDM4NS0 medium was harvested and the cells removed by centrifugation, followed by filtration through a 0.45 µm filter. Solid ammonium sulphate was added slowly to a final concentration of 60% (w/v) while stirring at 4 °C. Stirring was continued for a further 30 min, followed by centrifugation of the mixture at 6,500 g for 30 min at 4 °C. The pellet was dissolved in 1 mM EDTA in PBS and the ammonium sulphate removed via dialysis against 1 L of 1 mM EDTA/PBS (changed once), overnight at 4 °C using a 3.5 kDa dialysis cassette (Slide-a-Lyzer, Thermo Scientific (Pierce), Rockford, IL, USA) or dialysis cup (Thermo Scientific (Pierce), Rockford, IL, USA). The dialysed sample was concentrated further using a 10,000 molecular weight cut-off centrifugal concentrator (Vivaspin, Sartorius, Aubagne Cedex, France).
Yield Analysis
NS0 stable cell lines scFv-C L clone 2H4 and scFv-C L -WN19 clone AB4/23-25 (AB4) were cultured in CDM4NS0 medium in roller bottles. On day 0, cells were seeded at 0.3 x 10 6 cells/mL (100 mL total). Daily from day 3 onwards, 3 mL was removed from each bottle, the cells were assessed for viability using trypan blue exclusion and the supernatant was recovered (1,000 r.p.m., 5 min, Clements Orbital 310, Clements Medical Equipment, Pty.
Ltd., Somersby, Australia). Harvesting ceased once the viability reached ≤ 20%. The concentration of glycophorin-reactive scFv in each sample was estimated by glycophorin ELISA and a standard curve, which was generated using a known concentration of 1C3 Fab diluted in CDM4NS0 medium.
A similar procedure was used for recombinant mAb 1C3 stable cell line 3H4/221 (3H4), except that the cells were cultured in CDM4NS0 medium supplemented with 10% FBS and the standard curve was generated using hybridoma-derived, intact 1C3 in the glycophorin ELISA.
Detection of light and heavy chain gene integration into NS0 genome by PCR
Genomic DNA was extracted from NS0 cells using the GenElute kit (Sigma, Saint Louis, MO, USA) according to the manufacturer's instructions. PCR was performed as in 2.2 using 5 µL of the purified NS0 DNA, or approximately 10 ng plasmid DNA and the primer pairs VL3/VL4 (light chain-specific); VH3/VH4 (heavy chain-specific) or tg2/WN11 (amplifies heavy chain sequence plus peptide WN19 sequence, Table 1 ).
Red cell agglutination assays
Red cell agglutination assays were performed using protocols based on those described by Lilley et al. (1994) . For direct assays, 10 μL human blood (collected into citrate) was mixed on a plastic slide with dialysed, ammonium sulphate-concentrated scFv-C L and scFv-C L -WN19 reagents (40 μL). The amount of scFv-C L and scFv-C L -WN19 added per assay was estimated as 40 and 20 ng respectively, using the glycophorin ELISA. MAb 17D7 as ascitic fluid (1 μL as a 1:4 dilution in PBS), mAb 1B1 (0.5 μg) or 25 μL WNV-positive horse serum was added and the reagents were mixed for 2-3 seconds with a plastic rod, and then rocked manually for 5 min.
For indirect assays, 25 μL human blood (collected into citrate) was incubated with 1 μg scFv-C L -WN19 as 5 mL cell culture supernatant (CDM4NS0) and mixed gently for 30 min. The erythrocytes were pelleted at 1,000 r.p.m. (Jouan CR312, Jouan Ltd., Ilkeston, UK) and the supernatant was removed. MAbs 17D7 or 1B1 were added to 10 μL of the pre-absorbed erythrocytes as for the direct assays and made up to 50 μL final assay volume using the culture supernatant. In a modified format, the erythrocytes were pre-incubated with scFv-C L or scFv-C L -WN19 in cell culture medium containing 10% FBS. In this instance, the coated erythrocytes were mixed with 25 µL WNV-positive horse serum and the total reaction volume made up to 50 µL with PBS.
For agglutination assay using the recombinant mAb 1C3, 5 mL of cell culture supernatant, recovered from transfected NS0 cells and with an approximate concentration of 70 ng/mL, was incubated with 25 µL human blood for 30 min with gentle mixing. The treated erythrocytes were recovered by low-speed centrifugation (as described above) and 10 µL of the cells was mixed with 8 µL rabbit anti-human Ig (Dako, Glostrup, Denmark), or control rabbit antiserum (Dako, Glostrup, Denmark). The total reaction volume was made up to 50 µL using r1C3 cell culture supernatant.
Results
Glycophorin ELISA
To detect and quantify the recombinant autologous agglutination reagents, a glycophorinbinding ELISA, described originally by Lilley et al. (1994) , was optimized using checkerboard titration of glycophorin A and the Fab product of the hybridoma-derived mAb 1C3. The results (not shown) indicated that maximal binding of the antibody occurred when wells were coated with 50 ng glycophorin. These conditions were used in all subsequent
ELISAs. Standard curves were established with the hybridoma-derived 1C3 Fab or intact mAb to quantitate the scFv and full-length recombinant antibodies, respectively.
scFv-based agglutination reagents
The initial expression system examined was based on the scFv construct previously used for bacterial expression (Lilley et al., 1994; Coia et al., 1996) . This construct contains the variable region genes from mAb 1C3 linked to a constant light chain gene (scFv-C L ). The generation of mammalian expression vectors derived from the scFv-C L construct has been described previously (Hobson-Peters et al., 2008) . Two constructs were used in the studies reported here: one expressing the scFv-C L alone (pCDscFv) and another, pCDscFvWN19, which expresses a 19-residue West Nile virus (WNV) immunogenic peptide fused to the Cterminus of the scFv-C L protein (scFv-C L -WN19). Restriction enzyme recognition sites generating non-complementary overhangs were included either side of the insertion site for the WNV peptide coding sequence, to enable directional insertion of DNA encoding other diagnostic peptides. In addition, the bacterial signal peptide was replaced with an immunoglobulin leader sequence to facilitate secretion from transfected cells, and a Kozak consensus sequence was inserted to enhance protein expression.
Sequencing of the mammalian vectors revealed five nucleotide differences to the scFv-C L sequence (Lilley et al., 1994, Gregory Coia, CSIRO, Personal communication) . Three of the nucleotide differences were synonymous substitutions. One difference is predicted to lead to the substitution of an alanine with a threonine residue in the V L region. Since threonine residues are present at this position in other immunoglobulin sequences listed on the NCBI database (for example gi10834748), this substitution is unlikely to cause a functional change.
There is also a change from lysine to methionine in the C L region. As the function of the C L region is as a spacer to extend the attached peptide away from the erythrocyte surface, it is anticipated that this change is of little functional significance.
It has been shown previously through Western blot analysis of lysates of transiently transfected COS cells that the vectors (pCDscFv and pCDscFvWN19) direct the expression of proteins of the predicted mass and expected immunoreactivity with anti-(mouse Ig) antibody, WN19 specific-mAb and sera from WNV-infected horses (Hobson-Peters et al., 2008) . The sequence of additional experiments performed using these reagents is provided in figure 3A .
To determine whether a functional antigen-binding molecule was expressed, lysates of transfected COS cells were analyzed in the glycophorin ELISA. The results (Fig. 4A) confirmed that an antibody fragment capable of binding to glycophorin was expressed from both the pCDscFv and pCDscFvWN19 vectors.
To obtain sufficient scFv reagents for use in agglutination assays, NS0 cells stably transfected with pCDscFv and pCDscFvWN19 were generated. NS0 cells are used for the commercial production of recombinant antibodies (Barnes et al., 2000; Chu and Robinson, 2001) , as these cells are capable of secreting up to 2.7 mg/mL of recombinant protein (Zhou et al., 1997) . (Fig. 5A) , thus demonstrating the functionality of the eukaryotic-expressed scFv-C L -WN19 protein in the agglutination assay. As expected, there was no agglutination in a similar assay upon the addition of the negative control mAb 1B1, nor with scFv-C L and mAb 17D7.
No agglutination was observed with WNV-infected horse serum, perhaps due to the lower concentration of WN19-specific antibodies in the infected serum compared to ascitic fluid (data not shown).
To determine whether the strength of agglutination could be enhanced and to investigate the use of the recombinant scFvs secreted directly into the cell culture medium, without any further processing, indirect agglutination assays were performed. In these assays, human erythrocytes were incubated in harvested supernatant to allow adsorption of the reagents to the erythrocyte surface. The coated erythrocytes were washed and used in agglutination assays. Erythrocytes pre-coated with scFv-C L -WN19 reagent were cross-linked with the anti-WN19 mAb 17D7, to a greater extent than in the direct assay (Fig. 5B) . There was no agglutination in a similar assay upon addition of mAb 1B1, nor with another anti-WNV E protein mAb which binds a different epitope to mAb 17D7 and was also supplied in ascitic fluid (data not shown).
Pre-coated erythrocytes were agglutinated following addition of serum from a WNV-infected horse, but not with normal horse serum ( reagents (Fig. 5C ). The WNV-positive horse serum caused slight agglutination of erythrocytes from four different people, indicating that this reactivity was not specific to individual patients (data not shown).
In all, the results demonstrate that a functional autoagglutination reagent was produced by transfected mammalian cells. Although the concentration was too low for use of the supernatant in a direct assay without concentration, no further purification of the reagent was necessary.
Recombinant 1C3 antibody fusion proteins
A second set of experiments (summarized in Fig. 3B ) examined an alternative mammalian expression system that is used in our laboratory for the production of recombinant D-dimerspecific mAb 3B6 (Morris et al., 2004) . Lysates of transfected cells were examined by Western blot using antibodies specific for the human kappa and gamma chains, respectively. The light chain molecule had an apparent molecular mass of about 25 kDa (reduced, Fig. 6A ). The heavy chain had an apparent molecular mass of about 50 kDa (in reduced form) and migrated slightly more quickly than both its murine (hybridoma-derived) counterpart and the recombinant 3B6 heavy chain (Fig.   6B ). A distinct doublet was observed for the 1C3 H molecule, which could not be attributed to differences in glycosylation (Fig. 6C ) and was not apparent for the other heavy chain molecules. The 3B6 heavy chain expressed in both COS and NS0 cells ( Fig. 6B ; 3B6 H and r3B6 respectively) migrated a little more slowly and in COS cells was expressed to a similar level as the recombinant mAb 1C3 heavy chain molecule. Upon expression of plasmid pSV1C3V H WN19 (r1C3-WN19), it was noted that the increase in size of the heavy chain molecule was proportional to the size difference between scFv-C L -WN19 and scFv-C L (data not shown). Incubation of the r1C3-WN19 and r1C3 heavy chain molecules with PNGase F revealed that there was a greater difference in size between the treated and untreated r1C3-WN19 heavy chain molecule than that of r1C3 (Fig. 6C) . Together, these data suggested that a glycosylated peptide WN19 molecule was expressed on the end of the antibody Fc region.
However, this molecule was not recognised by mAb 17D7 (Fig. 6D) . The reason for this is not apparent as the presence of the correct DNA sequence for peptide WN19 in the r1C3-WN19 heavy chain plasmid was confirmed by sequencing.
To determine if a glycophorin-binding antibody could be expressed by pSV1C3V L and pSV1C3V H , COS cells were co-transfected with the vectors and cell lysates were examined in the glycophorin ELISA. The results (Fig. 4B) showed that glycophorin-binding antibodies were present in the lysate from the co-transfected cells. Surprisingly, reactivity was also observed in the lysate from cells transfected with pSV1C3V H alone, albeit less than that observed for the lysates from cells transfected with both pSV1C3V L and pSV1C3V H.
Together, these data demonstrate that the variable region sequences of mAb 1C3 were subcloned correctly into the original mAb 3B6 vectors to mediate the expression of a fulllength, chimeric (mouse-human) antibody capable of binding to glycophorin. Furthermore, it appeared that the WNV-specific peptide WN19 was fused to the C-terminus of the antibody heavy chain, although it was not recognized by mAb 17D7.
NS0 cells were co-transfected with pSV1C3V L and pSV1C3V H and selected for gpt expression with mycophenolic acid to obtain stable cell lines expressing the full-length antibody. Surviving cells were cloned by limiting dilution and several clones secreting glycophorin-reactive antibody were identified by ELISA. One clone (3H4) was expanded in serum-free CDM4NS0 medium in roller bottles. To demonstrate that the recombinant mAb 1C3 was functional in agglutination assays, erythrocytes were coated by incubation in culture supernatant from clone 3H4. Agglutination was clearly observed when anti-human Ig was added to the erythrocytes (Fig. 5D) . No agglutination was observed in the absence of crosslinking anti-human Ig, as is the case for the original hybridoma-derived mAb 1C3 (data not shown).
In light of the inability of mAb 17D7 to recognise the r1C3-WN19 heavy chain molecule produced in COS cells, it was considered unlikely that a similar molecule secreted by NS0 cells could be used in an agglutination assay and cross-linked with mAb 17D7. However, it was hoped that a stably expression r1C3-WN19 molecule may provide valuable insight into the effect of glycosylated fusion peptides at the 1C3 antibody Fc terminus on glycophorin binding, both in ELISA and erythrocyte agglutination assays. NS0 cells were stably cotransfected with plasmids pSV1C3V H WN19 and pSV1C3V L and the transfected cells were selected with mycophenolic acid. Surviving cells were cloned by limiting dilution and cloned cell supernatants were analyzed by the glycophorin ELISA. Despite several transfections, all of which yielded mycophenolic acid-resistant cloned cells, only one clone (3B7) was identified which secreted glycophorin-reactive antibody, albeit at barely detectable levels. To try to identify the reason for the lack of productive clones, PCR analysis was used to assess the presence of the heavy and light chain genes in the various stable clones. Three clones were examined: clone 3H4 (as described above -produces glycophorin-reactive recombinant mAb 1C3), clone 3B7 (r1C3-WN19) and clone 1A6. The last clone was produced following transfection with pSV1C3V H WN19 and pSV1C3V L , and was resistant to mycophenolic acid, but did not secrete detectable glycophorin-reactive antibody.
PCR amplification of genomic DNA from the clones with primers specific for the V H or V L region indicated stable integration of the heavy chain genes in all three clones, but the light chain gene was not apparent in clone 1A6. (Fig. 7A and B) . The latter result explains the lack of secretion of a functional antibody from 1A6 despite its resistance to mycophenolic acid, as the gpt gene is part of pSV1C3V H WN19. When primers specific for the C-terminal heavy chain domain (IgG 1 -3 ) and the WN19 peptide sequence were used, PCR product was observed for clones 3B7 and 1A6 (Fig. 7C ) as expected.
A further attempt to isolate a stable cell line secreting recombinant mAb 1C3 with the WN19 fusion protein was undertaken by re-transfecting clone 1A6 with pSV1C3V L and selecting for the presence of the hygromycin-resistance gene present on this plasmid. Despite the generation of several hygromycin-resistant cells, none secreted detectable glycophorinreactive antibody. PCR analysis of these clones demonstrated that the light chain gene was not present (data not shown).
Yield analysis
As a better understanding of the dynamics of expression of the recombinant fusion protein in culture is expected to be useful to optimise the yield of the protein, the concentration of glycophorin-reactive scFv protein and the viable cell density of three permanently transfected, cloned cell lines during in vitro culture was determined.. The analysis with the scFv-C Lsecreting clone 2H4 indicated that the maximum concentration of recombinant fusion protein and maximum cell viability count were detected after about six days of culture in serum-free CDM4NS0 medium (Fig. 8A) . Thereafter, both the viable cell count and the concentration of glycophorin-reactive scFv decreased. The results with the scFv-C L -WN19-secreting clone AB4 (Fig. 8B) showed that both parameters peaked at days 3 to 4 after culture initiation, and declined thereafter.
The third clone analysed was 3H4, which secretes recombinant mAb 1C3. In an attempt to increase yield, the clone was grown in CDM4NS0 medium supplemented with 10% FBS.
Although the yield of glycophorin-reactive antibody was greater than that from the scFv cell lines, with a peak concentration of about 700 ng/mL (Fig. 8C) , the antibody production curve was similar to those of the scFv stable cell lines, in that the maximum viable cell count and antibody concentration were detected on day 8.
These data differ from those obtained with other cell lines, where the recovery of antibody increases linearly after the maximal cell count has been reached (Bebbington et al., 1992; Brown et al., 1992; Bibila et al., 1994; Robinson et al., 1994; Keen and Hale, 1996) . To ensure that the antibody yields were not affected by an overgrowing population of nonsecreting cells from which integrated DNA had been removed, Geneticin selection was readministered at 200 µg/mL to the scFv-secreting cell lines. Very little cell death was observed in the stable cell lines at this concentration of Geneticin, while there was complete death of the wild type cells cultured under the same conditions (data not shown). There was a negligible increase (<10%) in secreted glycophorin-reactive scFv produced by the cells growing in the medium containing Geneticin.
Similarly, to ensure that the antibody yields from clone 3H4 which secretes recombinant mAb 1C3 were not affected by the presence of a mixed population of antibody-secreting and nonsecreting cells, the cell line was passaged 34 times and then re-cloned by limiting dilution.
Assessment of the supernatant from each clone in ELISA revealed that 97.3% (36/37) of the clones were expressing glycophorin-reactive antibody (data not shown). Therefore, it was concluded that the low yield was not due to instability of the integrated genes, which may have arisen due to premature removal of the mycophenolic acid selection.
Discussion
The autologous red cell agglutination assay is simple, rapid and has the unique advantage in that the sample itself contains the read-out system. The only external requirements are the agglutination reagent, a simple plastic well and a mixing rod to perform the agglutination reaction. These characteristics make the technology ideal for rapid response to outbreaks of emerging diseases due to the potential speed and ease with which new reagents could be manufactured for newly arising variants of current pathogens. For diseases that arise intermittently, the reagents could be stored for extended periods and deployed rapidly following outbreaks. The key to the widespread use of this technology is to develop a method for rapid, easy and economical production of the agglutination reagents with various fusion peptides. The aim of the current experiments was to develop and assess a mammalian expression system to fulfill these requirements. In particular, it was envisaged that the agglutination reagents, if secreted into culture supernatant, may be used without further purification to facilitate the rapid and economic deployment of the diagnostic assays. To that end, various vectors based on an anti-erythrocyte mAb were constructed to mediate secretion into culture medium of agglutination reagents. The vectors were developed to allow for the directional insertion of DNA encoding a variety of antigenic epitopes. The experiments show that culture supernatant may be used to mediate agglutination. However, they also suggest that greater yields are required for direct assays, and that further insight is required to ensure stable expression of some constructs.
Various expression systems have been used for the production of recombinant versions of molecules of biomedical interest, including bacterial, yeast, insect and mammalian cells.
Mammalian systems offer three distinct advantages. First, glycosylation of peptide WN19 is required for recognition by sera from infected animals (Hobson-Peters et al., 2008) . Although bacteria can glycosylate some antigenic moieties (McBride et al., 2007) , it is not certain whether this applies to all mammalian and viral epitopes requiring glycosylation and other post-translational modifications. It is likely that mammalian cells will provide more authentic modifications for antigens expressed naturally in mammalian cells, including those of viral origin. This is important as many newly emerging and re-emerging diseases are caused by viruses (Cleaveland et al. 2001) . Second, mammalian cells lines, in particular the mouse myeloma cell line NS0, have been used extensively in industry for the production of proteins including recombinant antibodies (Barnes et al., 2000; Chu and Robinson, 2001 ) and have been used in the manufacture of several commercial products such as as Zenapax (Dacliximab) (http://www.emea.auropa.eu/humansdocs/PDFs/EPAR/Zenapax/017599en6.pdf) and Synagis (Palivizumab) http://www.emea.europa.eu/humandocs/PDFs/EPAR/Synagis/190499en6.pdf).
AGEN Biomedical Ltd. has used this cell line for large-scale production of an anti-D-dimer antibody (Macfarlane et al., 2006) . As these cells grow in suspension, it is possible to cultivate them to high densities. Indeed, these cells when stably transfected, are capable of producing up to 2.7 g/L of recombinant protein (Zhou et al., 1997) . Other groups achieved as much as 1-2 mg/L (Ridder et al., 1995) or 400 mg/L (Howard et al., 2002 ) using large-scale transient transfection of COS cells. Third, the secretory apparatus of mammalian cells has been well-studied, and this understanding aids the design of expression vectors and the secretion of intact protein molecules into cell culture medium.
The current work examined two forms of recombinant antibody, the scFv and the full-length molecule. The scFv construct is a small antigen-reactive molecule. As a single chain is required, there is no need for disulphide bridges to link different proteins and this form of antibody is well suited to bacterial expression. The scFv previously used to produce autologous agglutination reagents in bacteria was adapted for expression in mammalian cells by inserting the relevant coding regions, together with mammalian leader and Kozak sequences, into a commercially available mammalian expression vector (Hobson-Peters et al., 2008) . Glycophorin-reactive scFv molecules (with and without the peptide WN19 fusion protein) were secreted by stably transfected NS0 cells at levels sufficient for the cell culture medium to be used without further processing in an indirect red cell agglutination assay. In two independent transfection events, six scFv-C L and eleven scFv-C L -WN19 stable transfectants were identified. Disappointingly, most of the clones secreted between 50 and 200 ng/mL glycophorin-reactive scFv, which was not sufficient for use in direct agglutination assays. Direct agglutination was achieved after concentration of the proteins in the cell culture medium.
The concentration of the secreted fusion protein produced by the stable NS0 cell lines did not increase by delaying harvest. Transfectants secreting different amounts of recombinant protein were expected (Barnes et al., 2001 (Barnes et al., , 2007 , due to the chromosomal integration site of the foreign gene (Wilson et al., 1990) . The low expression of the stable cells was unlikely to be due to poor cellular growth, as during the harvesting trial, the number of viable cells was within the range of growth of similar NS0 stable cell lines (Bebbington et al., 1992; Brown et al., 1992; Bibila et al., 1994; Robinson et al., 1994; Keen and Hale, 1996; Barnes et al., 2001 Barnes et al., , 2006 Barnes et al., , 2007 . Unexpectedly, the harvesting trial indicated that once the cell viability dropped below 50%, there was a decrease in the net glycophorin-reactive scFv protein in the cell culture medium. This contrasts with other published antibody production cycles of NS0 recombinants which show that the majority of recombinant antibody production occurs usually when the cell viability starts to decrease (Bebbington et al., 1992; Brown et al., 1992; Bibila et al., 1994; Robinson et al., 1994; Keen and Hale, 1996) . A possible explanation for the decrease in scFv accumulation seen in the current experiments is proteolytic degradation.
However, no specific degradation products were visible during Western blot analysis of the secreted NS0-produced scFv molecule (data not shown). In addition, analysis of cellular lysates did not indicate the presence of large amounts of protein retained within the cells (data not shown).
Production of a full-length recombinant antibody was undertaken to study of the effect of: a) extending the peptide away from the erythrocyte to make it more accessible to the crosslinking antibodies, b) using a bivalent antibody to increase avidity for the erythrocytes and c) having two peptide WN19 tails (due to the presence of one peptide per Fc of the intact antibody). In the commercial assays marketed by AGEN Biomedical, an Fab fragment was used to facilitate chemical coupling of the synthetic peptide on the hinge thiols, and to remove the Fc region which can cause false positive reactions due to the presence of anti-mouse antibodies or other interferents such as rheumatoid factor, present in human sera (M.
Gerometta, Personal communication). The expression of the mAb 1C3 variable regions with
human IgG constant regions will minimise these reactions when using human blood.
Although the affinity of the full-length antibody with the scFv version was not compared, Coia et al. (1996) showed that the scFv expressed in bacteria showed lower affinity for glycophorin than the hybridoma-derived Fab, while Dolezal et al. (1995) noted that there was little difference in the affinity shown by Fab expressed in hybridoma cells or bacteria. These results suggest that the full-length recombinant mAb 1C3 will have superior erythrocyte binding capacity compared to the scFv molecule.
The plasmids chosen for expression of the full-length molecule have been used in our laboratory to generate large quantities of a recombinant anti-D-dimer antibody in NS0 cells (Macfarlane et al., 2006) . This expression system uses two vectors which encode variable regions fused to human kappa light and IgG 1 constant regions respectively. Using a series of overlap PCRs, the mAb 1C3 variable region genes were engineered into the heavy and light chain expression vectors. A second heavy chain vector was also prepared which incorporated peptide WN19 after the carboxy terminus of the antibody heavy chain molecule. Culture medium from NS0 cloned cell lines stably transfected with the light and heavy chain plasmids (without WN19) mediated agglutination in an indirect assay without purification of the recombinant antibody. However, the concentration of antibody was shown to be about 700 ng/mL, which was too low to effect agglutination in a direct assay. This level is considerably below that observed in optimised cell lines, which suggests that greater levels of secreted protein can be achieved.
An interesting observation was that the harvesting profile of recombinant mAb 1C3 clone 3H4 was similar to that of the scFv stable clones, in that there was no increase in antibody accumulation post log-phase growth of the cells. Analysis of mRNA levels would assist in determining if the plateau in antibody accumulation is due to cessation of antibody synthesis, or if the antibody is being degraded by cellular proteases. It should be noted that the lower (and most intensely stained) band of the doublet observed for both the 1C3 H and 1C3 H WN19 molecules produced as COS lysates could not be attributed to glycosylation (Fig. 6C) and is possibly the result of N-terminal cleavage within the antibody variable region.
Despite the inability of mAb 17D7 to bind the r1C3-WN19 heavy chain molecule produced transiently in COS cells, several attempts to create a NS0 stable cell line expressing this molecule were made. It was envisaged that production of this molecule would enable investigation into the impact of the peptide on the antibody molecule's affinity and expression. Despite the ability of transiently transfected COS cells to express the heavy chain-WN19 fusion peptide, and the presence of heavy and light chain genes in one r1C3-WN19 NS0 clone (clone 3B7), very little secreted, glycophorin-reactive antibody was detected from the stable cell line. It can be argued that the visibly lower quantity of light and heavy chain PCR products, resulting from the amplification of the r1C3-WN19 transfected cell DNA, in comparison to the amount of product obtained when using the recombinant mAb 1C3 clone (3H4/221) DNA as a template, could be the result of fewer copies of the light and heavy chain genes. Previous studies have shown that an excess of light chain polypeptide is required for efficient mAb folding and assembly (Schlatter et al., 2005) . Furthermore, the heavy chain : light chain gene ratio can greatly affect the abundance of secreted mAb (Schlatter et al., 2005) . Southern blot (Bebbington et al., 1992) , or quantitative PCR analysis of the genomes of the stable cell lines produced in this study is required to determine the copy number of each gene. The secretion of functional r1C3-WN19 protein may have also been hindered by the peptide WN19 tails at the antibody terminus, preventing the correct folding of the antibody. However, expression of much larger and multi-glycosylated proteins at the end of other F(ab') 2 and intact antibodies have been reported without deleterious effect on antibody affinity and production (Gillies et al., 2002; Sharifi et al., 2002; Biela et al., 2003) .
In addition, the recombinant COS-produced 1C3 H and 1C3 H WN19 (data not shown) molecules were capable of binding glycophorin in the absence of the light chain molecule,
indicating that the requirement of the light chain for target recognition of 1C3 is negligible.
Thus, it seems unlikely that the poor expression of glycophorin reactive r1C3-WN19 was caused by the presence of the peptide tails, although this is the only difference between the recombinant mAb 1C3 and r1C3-WN19 constructs.
To adapt the production of the agglutination reagents described herein to commercial scale, several issues must be addressed. First, the expression levels by the mammalian cells must be increased significantly to achieve inexpensive production of reagents for use in direct agglutination assays. Greater yields were expected from the NS0 stable cell lines, particularly since NS0 cells are used frequently in the commercial production of recombinant antibodies.
However, the fact that both the scFv and full-length (recombinant 1C3) stable NS0 cell lines displayed similar secretion curves, which differ from those in other systems, suggests that there is site-specific proteolytic degradation occurring within the variable region of the 1C3
antibody. Second, these data highlight the importance of peptide choice in producing a successful agglutination reagent. While the scFv-C L -WN19 reagents were rapidly crosslinked by mAb 17D7, strong agglutination with the strongest WNV-positive horse serum was elusive. This indicates that peptide WN19 is not sufficiently immunogenic during WNV infection to induce an antibody response detectable by rapid immunoassays. The final issue to be addressed is the problem associated with the stable integration of both the heavy and light chain plasmids (for the production of the intact antibody) in a single cell. Enlisting a vector that encodes the light and heavy chain genes in a single plasmid may solve this problem.
However, the fact that the 1C3 heavy chain molecule appears to bind glycophorin in the absence of the light chain molecule suggests that co-expression of the two molecules may not be necessary.
In summary, recombinant scFv-C L -WN19 and recombinant mAb 1C3 molecules were functional in red cell agglutination assays when cross-linked with mAb 17D7 or WNVpositive horse anti-serum and anti-human immunoglobulin respectively. However, the mammalian expression systems did not yield recombinant protein at concentrations sufficient for use in direct agglutination assays without concentration or purification. Nevertheless, these studies have generated valuable plasmid constructs which will facilitate the efficient incorporation of alternative peptides and greater yields of these bi-functional agglutination reagents may be achieved by optimizing cell culture conditions or different vector systems to produce greater quantities of recombinant proteins. Fig.1 A and B) . The generation of fragments for the V H construct only is shown. For the V L construct, the strategy was similar except that primers VL2 -VL6 and pSVhygHuC k were used instead of VH2 -VH6 and pSVhygHuIgG 1 , respectively. The complete plasmids are depicted in Fig. 1C . The absorbance (OD 405 nm) of two replicates was plotted and the standard deviation shown. A. Amplify HuIgG 1-4 from pSVgptHuIgG 1 , minus the 3' stop codon but including the 5' NgoMIV site using TG17 and TG18 (incorporating XhoI and EagI sites). (Fig. 4A) Confirmation of expected protein expression by Western blot (HobsonPeters et al., 2008) Stable expression in NS0 cells
Yield analysis using glycophorin ELISA (Fig. 8A & B) Red cell agglutination assays (Fig. 5A-C 
